**[Our organization]’s Regulated Single-Use Device Reprocessing Cost Savings and Sustainability Policy**

**Note: In the EU, regulated single-use device reprocessing is known as remanufacturing.**

* [Organization] is committed to finding safe and effective ways to reduce cost, waste, greenhouse gas emissions and at the same time, build more resilience into the supply chain.
* [Organization] prioritizes the purchase of reusable or commercially reprocessed, ~~FDA~~-regulated “single-use” devices over disposable (“single-use”) devices, whenever possible.
* All original manufacturers of single-use devices that wish to sell products to [organization] are informed that [organization] intends to make optimal use of the devices we acquire, and that reprocessing is an important piece of this effort.
* [Organization] prioritizes reprocessing over recycling, given its higher ranking in the waste reduction hierarchy (reduce, reuse, recycle – in that order – because recycling consumes considerable energy and other environmental inputs).
* [Organization] also believes in science-based decision-making and thus, as we evaluate the cost, sustainability and other benefits of products, we will rely on credible measures and reports for their ability to reduce costs, greenhouse gas emissions and improve supply chain resilience. We prioritize in our evaluation of products reports from suppliers that include the total carbon footprint of their products and/or Life Cycle Assessments.
* Original device manufacturers are informed that representatives of their companies are expected to continue their practices as usual, including the technical support of clinical cases, and that such representatives are not to interfere in any way with [organization’s] reprocessing program, including engaging in any activity that undermines the reprocessing program and its financial savings.
* Original manufacturers of single-use devices or their representatives are not to disseminate literature at our facility that uses false claims or calls into question the safety or functionality of reprocessed SUDs, unless such literature is created independent of the OEM (not in any way funded or supported or written by the OEM). For example, industry funded studies that do not explain the chain of custody of reprocessed devices studied, are not to be disseminated in the hospital.
* The vendor has reviewed this policy standard and agrees to abide by its terms.

Signed,

Name, Company Name, Company

Date: Date: